BMO Capital Maintains Outperform on Phathom Pharmaceuticals, Lowers Price Target to $30
BMO Capital analyst Gary Nachman maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Outperform and lowers the price target from $35 to $30.
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development Agreement with the U.S. Department of Justice's Federal Bureau of Investigation.
Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $23
Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $23.
Seagate, Boot Barn, Tesla And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Nasdaq Composite gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Phathom Pharmaceuticals Announced Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic NERD; Both Vonoprazan 10 Mg And 20 Mg Doses Met Primary Endpoint
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) announced today positive topline results from PHALCON-NERD-301, a Phase 3 study evaluating the efficacy and safety of vonoprazan for the daily treatment of adults in symptomatic non-erosive gastroesophageal reflux disease (sGERD or NERD).
Dow Gains 150 Points After Fed Minutes
U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting.
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.
Nasdaq Rises Over 100 Points; Crude Oil Drops Sharply
U.S. stocks extended gains midway through trading, with the Dow Jones gaining around 250 points on Wednesday ahead of the release of minutes from the Fed's meeting.
Biogen’s 2nd Alzheimer’s Antibody, BeiGene’s Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Why OpGen Shares Are Trading Higher By 220%? Here Are 64 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
OpGen, Inc. (NASDAQ: OPGN) shares surged 220% to $0.3994 after the company announced topline data from its Unyvero urinary tract infections (UTI) clinical trial.